Hematopoietic stem cell transplantation (SCT) is a breakthrough curative treatment method for hematopoietic malignancy, and it has improved the vital prognosis and quality of life of patients. SCT was initiated in the late 1950s in the United States. The therapeutic outcomes of SCT markedly improved with the progression of treatment techniques and development of therapeutic drugs, with which the number of SCT applications has been increasing yearly. In the 2003 report, SCT was performed in about 50 000 adults per year worldwide. 1 However, SCT patients are exposed to a large amount of highly cytotoxic antitumor drugs, irradiation and immunosuppressors, and they have to overcome serious adverse events and complications, such as organ disorders and infections, associated with these. Among the various organ disorders, acute kidney injury (AKI) is one of the most important complications determining the vital prognosis of patients. 2, 3 The survival rate of patients treated with SCT markedly decreases early, within 6 months after transplantation, and then slowly decreases thereafter, reaching a plateau at about 5 years after transplantation, according to the newest data of the Japanese Data Center for Hematologic Cell Transplantation (http://www. jdchct.jdchct.or.jp/data/slide/2013). Physicians specialized in the kidney who are familiar with the perioperative period of SCT know that the development of AKI is involved in this high mortality in the early phase. 2, 4 In this issue of Bone Marrow Transplantation, Lopes et al. 5 reported a useful and concise review of the definition, diagnosis, incidence, and cause and prognosis associated with AKI following SCT based on the latest knowledge. According to this, making an early diagnosis of AKI and assessing the prognosis after SCT are limited even though new AKI classifications (RIFLE (2004), AKIN (2007) and KDIGO (2012) criteria) are used. To increase the ability to diagnose AKI after SCT, the measurement of new blood or urinary biomarkers, such as NGAL and L-FABP, is necessary. 6, 7 The frequency, onset time and cause of AKI after SCT vary among cases and are complex depending on whether stem cells are allogeneic or autologous and whether the preconditioning procedure is myeloablative or non-myeloablative. Therefore, cooperation by physicians familiar with the treatment of hematopoietic malignancy and SCT is essential to diagnose and treat AKI.
SCT patients experience severe kidney disease. Figure 1 shows the course of kidney disease development after allogeneic SCT. AKI develops early after SCT at a frequency of 27-66%, 4, 8 and this is critical and determines the short-and long-term mortalities of grafted patients. 5 Particularly, patients who develop AKI before stem cell engraftment (early AKI) are complicated by immunodeficiency, hemorrhagic tendency, infections and engraftment syndrome (capillary leak syndrome), elevating the mortality rate to about 70%. 9 A little o 1% of survivors of AKI develop chronic GvHD-associated nephrotic syndrome within several years 10, 11 and about 15-20% of them concomitantly develop CKD. 12 According to Lopes et al., 5 AKI after SCT is an important factor related to not only the mortality of patients but also the progression to CKD in the future. In a study reporting 158 SCT patients who survived for 3 years or longer after SCT, 17% developed stage 3 or severer CKD, and a 'past medical history of AKI after SCT' was the most strongly associated with the development of CKD (odds ratio: 9.92). 13 In a study in which the serum Cr level was prospectively investigated in 77 SCT patients followed for 10 years or longer (median duration of follow-up: 14.4 years (range: 10.5-20.2 years), the 10-year cumulative incidence of CKD (eGFR o60 mL/min/1.73 m 2 ) was 34% (26 cases). The factor related to CKD was also previous AKI in the transplantation period in this study, and its influence became stronger as the AKI severity based on the AKIN criteria increased (hazard ratio: stage 1, 3.27; stage 2, 6.98; stage 3, 14.8).
14 Thus, the early prediction, diagnosis and treatment of AKI after SCT may be very important to prevent CKD in long-term survivors of SCT. In addition, the rate of SCT patients aged 50 years or older was about 5% 10 years earlier, but it will exceed 30% with the spread of non-myeloablative conditioning 15 and possibly with a recent increase in the number of haploidentical SCT cases. A further increase in the incidence of post-transplant CKD in the future is predicted due to the aging of patients.
Medical care with hematopoietic SCT has recently progressed markedly, and the annual number of SCT cases has already exceeded the number of renal transplantations in the United States.
1 AKI that develops around the time of stem cell engraftment (early AKI) may be intractable or fatal in many cases. Moreover, some long-term survivors of SCT develop CKD, and their follow-up is also important. 16 Therefore, SCT is a medical care requiring cooperation by physicians specialized in the kidney who are familiar with malignant disease and transplantation therapies, accurately analyze the pathology of kidney disease, and have knowledge and experience facilitating the best treatment for kidney disease, in a wide sense, as 'onco-nephrologists'.
